Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$84.59
+5.9%
$80.33
$57.52
$117.19
$33.16B1.464.36 million shs3.46 million shs
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$155.96
$155.74
$93.34
$156.22
$10.30B0.55656,912 shsN/A
ResMed Inc. stock logo
RMD
ResMed
$256.44
+0.8%
$241.51
$179.42
$263.05
$37.57B0.78993,526 shs206,631 shs
STERIS plc stock logo
STE
STERIS
$239.01
+0.9%
$234.89
$200.98
$252.79
$23.51B0.94545,234 shs78,888 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
-0.20%-3.81%-5.53%+8.55%-31.55%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.00%0.00%0.00%0.00%0.00%
ResMed Inc. stock logo
RMD
ResMed
+0.23%+1.05%+4.62%+14.84%+23.52%
STERIS plc stock logo
STE
STERIS
+0.63%-1.69%-2.57%+6.94%+8.63%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
DexCom, Inc. stock logo
DXCM
DexCom
4.8003 of 5 stars
3.55.00.04.72.22.51.9
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
N/AN/AN/AN/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
4.1288 of 5 stars
2.31.03.34.62.71.71.3
STERIS plc stock logo
STE
STERIS
4.8817 of 5 stars
3.35.03.33.82.82.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DexCom, Inc. stock logo
DXCM
DexCom
2.95
Moderate Buy$98.5016.45% Upside
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.00
N/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
2.60
Moderate Buy$259.331.13% Upside
STERIS plc stock logo
STE
STERIS
2.63
Moderate Buy$263.8310.38% Upside

Current Analyst Ratings Breakdown

Latest HRC, RMD, DXCM, and STE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
DexCom, Inc. stock logo
DXCM
DexCom
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$102.00
5/30/2025
DexCom, Inc. stock logo
DXCM
DexCom
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$104.00
5/29/2025
STERIS plc stock logo
STE
STERIS
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$263.00
5/22/2025
DexCom, Inc. stock logo
DXCM
DexCom
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$82.00 ➝ $102.00
5/20/2025
ResMed Inc. stock logo
RMD
ResMed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$286.00
5/19/2025
STERIS plc stock logo
STE
STERIS
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$240.00 ➝ $260.00
5/16/2025
STERIS plc stock logo
STE
STERIS
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/16/2025
STERIS plc stock logo
STE
STERIS
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$265.00 ➝ $280.00
5/15/2025
STERIS plc stock logo
STE
STERIS
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$250.00 ➝ $250.00
5/5/2025
DexCom, Inc. stock logo
DXCM
DexCom
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$90.00 ➝ $93.00
5/2/2025
DexCom, Inc. stock logo
DXCM
DexCom
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$100.00 ➝ $90.00
(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DexCom, Inc. stock logo
DXCM
DexCom
$4.03B8.22$2.38 per share35.59$5.38 per share15.72
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$3.02B3.41$9.29 per share16.79$28.56 per share5.46
ResMed Inc. stock logo
RMD
ResMed
$4.69B8.03$9.33 per share27.49$33.11 per share7.75
STERIS plc stock logo
STE
STERIS
$5.46B4.31$14.46 per share16.53$67.33 per share3.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DexCom, Inc. stock logo
DXCM
DexCom
$576.20M$1.3463.1134.391.7112.90%30.05%10.00%7/24/2025 (Estimated)
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$248.50M$3.7241.9221.72N/A8.23%23.07%8.96%N/A
ResMed Inc. stock logo
RMD
ResMed
$1.02B$8.9128.7624.751.7526.15%25.67%18.59%7/30/2025 (Estimated)
STERIS plc stock logo
STE
STERIS
$614.64M$6.2038.5424.07N/A11.26%14.21%9.13%8/5/2025 (Estimated)

Latest HRC, RMD, DXCM, and STE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q4 2025
STERIS plc stock logo
STE
STERIS
$2.59$2.74+$0.15$1.47$1.47 billion$1.48 billion
5/1/2025Q1 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.33$0.32-$0.01$0.27$1.02 billion$1.04 billion
4/23/2025Q3 2025
ResMed Inc. stock logo
RMD
ResMed
$2.36$2.37+$0.01$2.48$1.28 billion$1.29 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$0.960.62%N/A25.81%N/A
ResMed Inc. stock logo
RMD
ResMed
$2.120.83%N/A23.79%13 Years
STERIS plc stock logo
STE
STERIS
$2.280.95%N/A36.77%20 Years

Latest HRC, RMD, DXCM, and STE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/7/2025
STERIS plc stock logo
STE
STERIS
quarterly$0.571.01%6/10/20256/10/20256/26/2025
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.530.9%5/8/20255/8/20256/12/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DexCom, Inc. stock logo
DXCM
DexCom
0.55
1.50
1.32
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.97
1.38
1.05
ResMed Inc. stock logo
RMD
ResMed
0.12
3.41
2.49
STERIS plc stock logo
STE
STERIS
0.29
1.96
1.39

Institutional Ownership

CompanyInstitutional Ownership
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
76.45%
ResMed Inc. stock logo
RMD
ResMed
54.98%
STERIS plc stock logo
STE
STERIS
94.69%

Insider Ownership

CompanyInsider Ownership
DexCom, Inc. stock logo
DXCM
DexCom
0.32%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.69%
ResMed Inc. stock logo
RMD
ResMed
0.71%
STERIS plc stock logo
STE
STERIS
1.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
DexCom, Inc. stock logo
DXCM
DexCom
10,300392.11 million390.85 millionOptionable
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
10,00066.05 million65.59 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
9,980146.63 million145.59 millionOptionable
STERIS plc stock logo
STE
STERIS
17,78798.37 million97.32 millionOptionable

Recent News About These Companies

Steris discloses pay for top executives and its median employee

New MarketBeat Followers Over Time

Media Sentiment Over Time

DexCom stock logo

DexCom NASDAQ:DXCM

$84.59 +4.75 (+5.95%)
As of 12:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Hill-Rom stock logo

Hill-Rom NYSE:HRC

Hill-Rom Holdings, Inc. operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions. The Front Line Care segment offers respiratory care products and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL.

ResMed stock logo

ResMed NYSE:RMD

$256.44 +1.92 (+0.75%)
As of 12:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

STERIS stock logo

STERIS NYSE:STE

$239.01 +2.10 (+0.89%)
As of 12:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.